Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Elsulfavirine
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Elpida is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of HIV Infections.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
January 24, 2022
Lead Product(s) : Elsulfavirine
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : VM-1500A-LAI
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase II/ Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : VM-1500A-LAI is a drug candidate, which is currently being evaluated in phase II/ phase III clinical studies for the treatment of HIV Infections.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
January 24, 2022
Lead Product(s) : VM-1500A-LAI
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase II/ Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Elsulfavirine
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Elsulfavirine is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of HIV Infections.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
December 21, 2021
Lead Product(s) : Elsulfavirine
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : VM-1500A-LAI
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase I/ Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : VM-1500A-LAI is a drug candidate, which is currently being evaluated in phase I/ phase II clinical studies for the treatment of HIV Infections.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
December 20, 2021
Lead Product(s) : VM-1500A-LAI
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase I/ Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Elsulfavirine
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Elsulfavirine is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of COVID-19.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
December 08, 2021
Lead Product(s) : Elsulfavirine
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : AV5080
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Dose Range Study to Evaluate the Efficacy and Safety of AV5080 in Patients With Influenza
Details : AV5080 is a drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Influenza, Human.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
October 27, 2021
Lead Product(s) : AV5080
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : AV5080
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Study Evaluating the Efficacy and Safety of AV5080 in Patients With Uncomplicated Influenza
Details : AV5080 is a drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Influenza, Human.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
October 26, 2021
Lead Product(s) : AV5080
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Favipiravir
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Approved FDF
Sponsor : Russian Direct Investment Fund
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : The efficacy and safety of Avifavir was statistically significantly demonstrated in two Phase 2 and Phase 3 clinical trials in 460 medium severe and severely ill COVID-19 patients conducted between April and October 2020.
Product Name : Avifavir
Product Type : Miscellaneous
Upfront Cash : Inapplicable
March 09, 2021
Lead Product(s) : Favipiravir
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Approved FDF
Sponsor : Russian Direct Investment Fund
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : VM1500A
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Phase 2a study aims to select a therapeutic dose and assess safety and efficacy of VM-1500A-LAI multiple injections in HIV+ virally suppressed patients vs a marketed Elpida®-based once-daily regimen.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
May 04, 2020
Lead Product(s) : VM1500A
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Elsulfavirine,Favipiravir
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Viriom Initiates Phase 2 Clinical Study of Elsulfavirine for Treatment of COVID-19
Details : Phase 2 clinical study expands the ongoing research into elsulfavirine, which includes confirmation of elsulfavirine antiviral activity against COVID-19 infection by Zhejiang University in China.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
April 08, 2020
Lead Product(s) : Elsulfavirine,Favipiravir
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable